TOT BIOPHARM International Company Limited

SEHK:1875 Stock Report

Market Cap: HK$1.5b

TOT BIOPHARM International Past Earnings Performance

Past criteria checks 2/6

TOT BIOPHARM International has been growing earnings at an average annual rate of 47.3%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 74.7% per year. TOT BIOPHARM International's return on equity is 1.2%, and it has net margins of 0.9%.

Key information

47.3%

Earnings growth rate

56.0%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate74.7%
Return on equity1.2%
Net Margin0.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

TOT BIOPHARM International Company Limited's (HKG:1875) Low P/S No Reason For Excitement

Dec 18
TOT BIOPHARM International Company Limited's (HKG:1875) Low P/S No Reason For Excitement

We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

Jun 07
We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More

May 21
The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More

Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?

Mar 18
Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?

There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues

Dec 28
There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues

Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?

Nov 23
Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?

We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt

May 18
We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Jul 27
Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued

Mar 26
An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Feb 03
Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Revenue & Expenses Breakdown

How TOT BIOPHARM International makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SEHK:1875 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 249739589100
31 Mar 24877-14549102
31 Dec 23781-38509104
30 Sep 23684-44454117
30 Jun 23588-49400131
31 Mar 23515-50333141
31 Dec 22442-50267151
30 Sep 22339-106202174
30 Jun 22235-162137196
31 Mar 22156-212108205
31 Dec 2176-26179215
30 Sep 2154-26876220
30 Jun 2133-27473225
31 Mar 2128-28173230
31 Dec 2022-28873235
30 Sep 2028-30193225
30 Jun 2034-313113215
31 Mar 2040-306120203
31 Dec 1945-299127191
31 Dec 1839-26894189
31 Dec 1752-14953106

Quality Earnings: 1875 has a large one-off loss of CN¥2.5M impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: 1875 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1875 has become profitable over the past 5 years, growing earnings by 47.3% per year.

Accelerating Growth: 1875 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 1875 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (7.4%).

Return on Equity

High ROE: 1875's Return on Equity (1.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 04:46
End of Day Share Price 2025/01/28 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TOT BIOPHARM International Company Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xin Qiu LinGuoyuan Securities (HK) Ltd
Yue-Kwong LuiJefferies LLC